ReviewAging cell2018
Aging and Alzheimer's disease: Comparison and associations from molecular to system level.
Review in Aging cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Psychometric properties of the NIH Toolbox Cognition Battery composites in older adults at risk for Alzheimer's disease and related dementias: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- The global prevalence of mild cognitive impairment in geriatric population with emphasis on influential factors: a systematic review and meta-analysis.BMC geriatrics · 2025Pooled it
- Repurposing effect of cardiovascular-metabolic drug to increase lifespan: a systematic review of animal studies and current clinical trial progress.Frontiers in pharmacology · 2024Pooled it
- Herbal Therapeutics for Alzheimer's Disease: Ancient Indian Medicine System from the Modern Viewpoint.Current neuropharmacology · 2023Pooled it
- Nut Consumption for Cognitive Performance: A Systematic Review.Advances in nutrition (Bethesda, Md.) · 2021Pooled it
- Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial.The journal of prevention of Alzheimer's disease · 2022Trial
- Prevalence and Risk of Mild Cognitive Impairment Among Chinese Adults Aged 60 Years and Above: A Cross-Sectional Study Based on National Data.Actas espanolas de psiquiatria · 2026Article
- Network-based discovery of regulatory drivers of cognitive decline in alzheimer's disease.npj aging · 2026Article
- Targeting inflammaging in Alzheimer's disease: molecular pathways and emerging pharmacotherapies.Inflammopharmacology · 2026Review
- Cellular Senescence of Patient-derived Fibroblasts Reveals the Mid-old Stage as a Critical Window for Transcriptomic Signatures Linked to Alzheimer's Disease Biomarkers and Classification.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Distribution of dementia severity and its functional correlates in community-dwelling older adults in Vietnam.BMC geriatrics · 2026Article
- Aloe-emodin inhibits p38 MAPK pathway in Alzheimer's disease treatment: a network pharmacology and experimental verification.Journal of molecular histology · 2026Article
- Article
- The influence of pain on the cognitive function of middle-aged and older couples in China.BMC psychology · 2026Article
- Article
- Elevated NaInternational journal of molecular sciences · 2026Article
- Assessing the Roles of Aging, Estrogen, Nutrition, and Neuroinflammation in Women and Their Involvement in Alzheimer's Disease-A Narrative Overview.International journal of molecular sciences · 2026Review
- Age-dependent vulnerability to spatial memory interference in APP/PS1 mice.Frontiers in aging neuroscience · 2026Article
- Association between depression and cognitive function in middle-aged and older adults: a study based on the health and retirement study.Frontiers in psychology · 2026Article
- Ginkgolide as a Promising Multi-Target Therapeutic for Alzheimer's Disease: Targeting ApoE4 and Beyond.Current pharmaceutical design · 2026Article
104 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease is the most prevalent cause of dementia, which is defined by the combined presence of amyloid and tau, but researchers are gradually moving away from the simple assumption of linear causality proposed by the original amyloid hypothesis. Aging is the main risk factor for Alzheimer's disease that cannot be explained by amyloid hypothesis. To evaluate how aging and Alzheimer's disease are intrinsically interwoven with each other, we review and summarize evidence from molecular, cellular, and system level. In particular, we focus on study designs, treatments, or interventions in Alzheimer's disease that could also be insightful in aging and vice versa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.